4-(4-Hydroxy-3-methoxy-phenyl)-4-oxo-buttersaeure | 14617-13-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-Hydroxy-3-methoxy-phenyl)-4-oxo-buttersaeure
• 英文别名: β-(4-Hydroxy-3-methoxybenzoyl)-propionsaeure；4-(4-hydroxy-3-methoxy-phenyl)-4-oxo-butyric acid；3-(4-Hydroxy-3-methoxybenzoyl)propionic acid；4-(4-Hydroxy-3-methoxyphenyl)-4-oxobutanoic acid
• CAS: 14617-13-1
• 化学式: C₁₁H₁₂O₅
• 分子量: 224.213
• InChiKey: MITUCWWQUUFNNX-UHFFFAOYSA-N

物化性质

• 熔点：
  175-176 °C
• 沸点：
  472.6±35.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-Hydroxy-3-methoxy-phenyl)-4-oxo-buttersaeure 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone
  参考文献：
  名称：

  PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

  摘要：

  提供一种新颖的吡唑酮衍生物， represented by the following general formula (1)，该衍生物可用作药物，并具有磷酸二酯酶抑制作用： 其中 R1，R2：C1-6烷基；R3，R4：H，X，C1-6烷氧基；Z：O，S；A：AA，BB，其中AA代表 其中BB代表 其中R5：H，C1-6烷基；R6，R7：C1-6烷基。

  公开号：

  EP2168960A1
• 作为产物：
  描述：

  3-(3,4-二甲氧基苯甲酰)丙酸 在 氢碘酸 作用下， 生成 4-(4-Hydroxy-3-methoxy-phenyl)-4-oxo-buttersaeure
  参考文献：
  名称：

  从间苯二酚系列中还原 β-苯甲酰基丙酸

  摘要：

  与其两种半醚和许多其他琥珀酰苯酚相比，2,4-二羟基-苯甲酰丙酸（琥珀酰间苯二酚）不能通过催化或用 NaBH4 还原到羟基酸的水平。原因进行了讨论。铅阴极上琥珀酰苯酚的电解还原不仅产生 γ-芳基-γ-羟基丁酸，而且产生它们的频哪醇样二聚体，它们通过质子催化内酯化。4-甲氧基苯基丁内酯可以用 BBr3 去甲基化。该反应不适用于 4-甲氧基-2-羟基苯基-丁内酯。

  DOI：

  10.1002/ardp.19662990614

文献信息

• [EN] MACROLIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES A BASE DE MACROLIDES
  申请人：GLAXO GROUP LTD

  公开号：WO2002050091A1

  公开（公告）日：2002-06-27

  The present invention relates to 11,12 η lactone ketolides of formula (I) wherein R, R?1, R2, R3¿ are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式（I）的11,12-η内酯酮类化合物，其中R，R?1，R2，R3¿如本文所定义，并且其药学上可接受的盐和溶剂合物，以及其制备过程和在治疗或预防人类或动物体内的全身性或局部细菌感染中的应用。
• Macrolide antibiotics
  申请人：——

  公开号：US20040077557A1

  公开（公告）日：2004-04-22

  The present invention relates to 11,12 &ggr; lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及公式（I）中的11,12 &ggr;内酯酮类化合物，其中R、R1、R2、R3如本文所定义的，以及其药学上可接受的盐和溶剂化物，以及它们的制备方法及在人或动物体内治疗或预防全身或局部细菌感染中的应用。
• Macrolide Antibiotics
  申请人：ALIHODZIC Sulejman

  公开号：US20060211636A1

  公开（公告）日：2006-09-21

  The present invention relates to 11,12 γ lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式(I)的11,12-γ内酯酮类化合物，其中R、R1、R2、R3如定义所述，以及其药学上可接受的盐和溶剂化物，以及其制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。
• Chromosomal alterations and male infertility
  作者：A. Antonelli、L. Gandini、P. Petrinelli、L. Marcucci、R. Elli、F. Lombardo、F. Dondero、Andrea Lenzi

  DOI：10.1007/bf03343793

  日期：2000.11

  Reduced male fertility can be caused by genetic factors affecting gamete formation or function; in particular, chromosome abnormalities are a possible cause of male subfertility as shown by their higher frequency in infertile men than in the general male population. Meiotic studies in a number of these males have shown spermatogenesis breakdown, often related to alterations in the process of chromosome synapsis. Indeed, any condition that can interfere with X-Y bivalent formation and X-chromosome inactivation is critical to the meiotic process; furthermore, asynapsed regions may themselves represent a signal for the meiotic checkpoint that eliminates spermatocytes with synaptic errors. We performed cytogenetic, hormonal and seminal studies in 333 infertile patients selected because azoospermic, severely oligozoospermic or normozoospermic with failure to fertilize the partner's oocytes in an in vitro fertilization (IVF) program. Our findings: 1) confirm the high incidence of chromosomal anomalies among infertile males; 2) highlight the relevance in male infertility of quantitative/positional modifications of the constitutive heterochromatin; and 3) underline the relevance of cooperation between andrologists and cytogenetists prior to every kind of assisted reproduction, above all prior to intracytoplasmic sperm injection, in which selective hurdles eliminating abnormal germ cells are bypassed. (C) 2000, Editrice Kurtis.
• MACROLIDE ANTIBIOTICS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1363925A1

  公开（公告）日：2003-11-26